The 36-month beta value for ENSC is also noteworthy at 0.84. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ENSC is 13.50M, and at present, short sellers hold a 1.33% of that float. The average trading volume of ENSC on October 16, 2024 was 1.82M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ENSC) stock’s latest price update
Ensysce Biosciences Inc (NASDAQ: ENSC)’s stock price has plunge by -0.94relation to previous closing price of 0.17. Nevertheless, the company has seen a -10.04% plunge in its stock price over the last five trading sessions. accesswire.com reported 2024-10-08 that ~ Dr. Lynn Kirkpatrick to Present Latest Clinical Data for PF614 and PF614-MPAR ~ ~ Dr. William Schmidt to Deliver Opening Remarks as Summit Chair ~ SAN DIEGO, CA / ACCESSWIRE / October 8, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or “Company”), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced that Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, will present at the 18th Annual Pain Therapeutics Summit taking place on October 28 and 29, 2024 in Boston, MA. Dr.
ENSC’s Market Performance
Ensysce Biosciences Inc (ENSC) has seen a -10.04% fall in stock performance for the week, with a -51.19% decline in the past month and a -64.02% plunge in the past quarter. The volatility ratio for the week is 14.49%, and the volatility levels for the past 30 days are at 9.78% for ENSC. The simple moving average for the last 20 days is -31.01% for ENSC stock, with a simple moving average of -74.47% for the last 200 days.
ENSC Trading at -50.01% from the 50-Day Moving Average
After a stumble in the market that brought ENSC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.83% of loss for the given period.
Volatility was left at 9.78%, however, over the last 30 days, the volatility rate increased by 14.49%, as shares sank -51.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.54% lower at present.
During the last 5 trading sessions, ENSC fell by -10.04%, which changed the moving average for the period of 200-days by -83.65% in comparison to the 20-day moving average, which settled at $0.2441. In addition, Ensysce Biosciences Inc saw -84.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ENSC
Current profitability levels for the company are sitting at:
- -6.72 for the present operating margin
- -3.38 for the gross margin
The net margin for Ensysce Biosciences Inc stands at -7.84. The total capital return value is set at -6.49. Equity return is now at value -380.55, with -246.41 for asset returns.
Based on Ensysce Biosciences Inc (ENSC), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -21.83. The debt to equity ratio resting at 0.25. The interest coverage ratio of the stock is -5.93.
Currently, EBITDA for the company is -10.72 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 1.21. The receivables turnover for the company is 6.41for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.88.
Conclusion
In summary, Ensysce Biosciences Inc (ENSC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
